Aptose Biosciences Inc. (APTO) Receives Buy Rating from Roth Capital
Several other analysts have also recently weighed in on the company. Royal Bank Of Canada restated an outperform rating and set a $23.00 price target on shares of Aptose Biosciences in a report on Saturday, June 25th. Zacks Investment Research cut Aptose Biosciences from a hold rating to a sell rating in a report on Friday, August 12th. RBC Capital Markets reiterated an outperform rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Finally, Canaccord Genuity reissued a buy rating and issued a $7.00 price target on shares of Aptose Biosciences in a research note on Saturday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $12.30.
Shares of Aptose Biosciences (NASDAQ:APTO) traded down 9.17% during mid-day trading on Friday, hitting $2.18. 35,115 shares of the company were exchanged. The company’s market capitalization is $28.10 million. The firm has a 50 day moving average of $2.22 and a 200 day moving average of $2.47. Aptose Biosciences has a 12-month low of $1.92 and a 12-month high of $6.40.
An institutional investor recently bought a new position in Aptose Biosciences stock. Bank of Montreal Can acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned 0.43% of Aptose Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.47% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.